Year-end Sale % OFF 
Abstract
B7-H3 overexpression is associated with poor prognosis in various cancers. DS-7300 is an antibody drug conjugate composed of an anti–B7-H3 IgG1 monoclonal antibody conjugated to an exatecan derivative payload with a drug to antibody ratio of ∼4. It has shown potent preclinical antitumor activity. Here, we report preliminary results from a phase 1/2 trial of DS-7300 in pts with advanced solid tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
